Fulgent Genetics Raises FY24 Adj EPS Guidance from $(0.30) to $0.33 vs $(0.39) Est; Affirms Sales Guidance Of $280.00M vs $282.16M Est
Benzinga Newsdesk 1 year ago
NewsGuidance
Outlook:For the full year 2024, Fulgent expects:Core Revenue of approximately $280 millionGAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per shareNon-GAAP loss improvement from
Outlook:
For the full year 2024, Fulgent expects:
- Core Revenue of approximately $280 million
- GAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per share
- Non-GAAP loss improvement from approximately ($0.30) loss per share to approximately $0.33 income per share
- Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024*
*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company's ongoing stock repurchase program or other expenditures outside the ordinary course of business.